203 related articles for article (PubMed ID: 24373580)
1. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.
Holmgaard DB; Mygind LH; Titlestad IL; Madsen H; Pedersen SS; Johansen JS; Pedersen C
BMC Pulm Med; 2013 Dec; 13():77. PubMed ID: 24373580
[TBL] [Abstract][Full Text] [Related]
2. Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease.
James AJ; Reinius LE; Verhoek M; Gomes A; Kupczyk M; Hammar U; Ono J; Ohta S; Izuhara K; Bel E; Kere J; Söderhäll C; Dahlén B; Boot RG; Dahlén SE;
Am J Respir Crit Care Med; 2016 Jan; 193(2):131-42. PubMed ID: 26372680
[TBL] [Abstract][Full Text] [Related]
3. High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity.
Gumus A; Kayhan S; Cinarka H; Kirbas A; Bulmus N; Yavuz A; Sahin U; Ozkaya S
Tohoku J Exp Med; 2013 Feb; 229(2):163-70. PubMed ID: 23364142
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling.
Lai T; Wu D; Chen M; Cao C; Jing Z; Huang L; Lv Y; Zhao X; Lv Q; Wang Y; Li D; Wu B; Shen H
Respir Res; 2016 Mar; 17():31. PubMed ID: 27013031
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study.
Sørensen AK; Holmgaard DB; Mygind LH; Johansen J; Pedersen C
J Inflamm (Lond); 2015; 12():20. PubMed ID: 25908927
[TBL] [Abstract][Full Text] [Related]
6. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
[TBL] [Abstract][Full Text] [Related]
7. YKL-40: may be use as a new inflammatory biomarker in obstructive sleep apnea syndrome?
Duru S; Yüce G; Fırat H; Şimşek B; Uçar F; Ardıç S; Kurt EB
Tuberk Toraks; 2015 Sep; 63(3):158-64. PubMed ID: 26523896
[TBL] [Abstract][Full Text] [Related]
8. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
Chen G; Yang T; Gu Q; Ni XH; Zhao ZH; Ye J; Meng XM; Liu ZH; He JG; Xiong CM
Respirology; 2014 May; 19(4):608-15. PubMed ID: 24689969
[TBL] [Abstract][Full Text] [Related]
10. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
[TBL] [Abstract][Full Text] [Related]
11. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes.
Lin CH; Li HY; Jiang YD; Chang TJ; Chuang LM
Clin Endocrinol (Oxf); 2013 Aug; 79(2):185-91. PubMed ID: 22901243
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
[TBL] [Abstract][Full Text] [Related]
13. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease.
Lee SH; Lin CY; Wang PH; Han CP; Yang SF; Chang JT; Lee MC; Lin LY; Lee MS
J Clin Lab Anal; 2012 May; 26(3):136-42. PubMed ID: 22628227
[TBL] [Abstract][Full Text] [Related]
14. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.
Kunz LI; van't Wout EF; van Schadewijk A; Postma DS; Kerstjens HA; Sterk PJ; Hiemstra PS
Respir Res; 2015 Dec; 16():154. PubMed ID: 26696093
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation.
Mørup AM; Kornblit B; Johansen JS; Masmas TN; Madsen HO; Vindeløv L; Garred P
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1299-307. PubMed ID: 21232622
[TBL] [Abstract][Full Text] [Related]
16. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.
Konradsen JR; James A; Nordlund B; Reinius LE; Söderhäll C; Melén E; Wheelock AM; Lödrup Carlsen KC; Lidegran M; Verhoek M; Boot RG; Dahlén B; Dahlén SE; Hedlin G
J Allergy Clin Immunol; 2013 Aug; 132(2):328-35.e5. PubMed ID: 23628340
[TBL] [Abstract][Full Text] [Related]
17. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease.
Otsuka K; Matsumoto H; Niimi A; Muro S; Ito I; Takeda T; Terada K; Yamaguchi M; Matsuoka H; Jinnai M; Oguma T; Nakaji H; Inoue H; Tajiri T; Iwata T; Chin K; Mishima M
Respiration; 2012; 83(6):507-19. PubMed ID: 21968467
[TBL] [Abstract][Full Text] [Related]
18. Plasma YKL-40 levels are elevated in patients with chronic heart failure.
Rathcke CN; Kistorp C; Raymond I; Hildebrandt P; Gustafsson F; Lip GY; Faber J; Vestergaard H
Scand Cardiovasc J; 2010 Apr; 44(2):92-9. PubMed ID: 19961288
[TBL] [Abstract][Full Text] [Related]
19. Calprotectin--a marker of mortality in COPD? Results from a prospective cohort study.
Holmgaard DB; Mygind LH; Titlestad I; Madsen H; Pedersen SS; Mortensen OH; Pedersen C
COPD; 2013 Oct; 10(5):581-7. PubMed ID: 23844942
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI.
Cetin M; Kocaman SA; Canga A; Kırbaş A; Yılmaz A; Erdoğan T; Akgül O; Uğurlu Y; Durakoğlugil ME
Herz; 2013 Mar; 38(2):202-9. PubMed ID: 22955689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
